Alector (ALEC) Share-based Compensation (2018 - 2026)
Alector's (ALEC) quarterly Share-based Compensation came in at $2.6 million in Q2 2026, down 63.04% year-over-year from $7.1 million in Q2 2025, and down 10.25% quarter-over-quarter from $2.9 million in Q1 2026.
Analysis
Alector (ALEC) Share-based Compensation (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Share-based Compensation for 9 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Share-based Compensation fell 63.04% year-over-year to $2.6 million in Q2 2026; TTM through Jun 2026 was $16.8 million, a 51.64% decrease from a year earlier, with the FY2025 full-year figure at $26.7 million, down 36.83% from the prior year.
- Share-based Compensation was $2.6 million for Q2 2026 at Alector, down from $2.9 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $13.7 million in Q2 2022 and troughed at $2.6 million in Q2 2026.
- A 5-year average of $9.4 million and a median of $10.1 million in 2023 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation increased 18.09% in 2022 and tumbled 65.18% in 2026, its largest moves.
- Over 5 years, Share-based Compensation stood at $11.0 million in 2022, then increased by 5.28% to $11.5 million in 2023, then fell by 11.52% to $10.2 million in 2024, then slumped by 52.58% to $4.8 million in 2025, then tumbled by 46.11% to $2.6 million in 2026.
- The last three Share-based Compensation figures came in at $2.6 million (Q2 2026), $2.9 million (Q1 2026), and $4.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | 2.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.61 Mn |
| Mar 31, 2026 | 2.91 Mn |
| Dec 31, 2025 | 4.84 Mn |
| Sep 30, 2025 | 6.40 Mn |
| Jun 30, 2025 | 7.06 Mn |
| Mar 31, 2025 | 8.35 Mn |
| Dec 31, 2024 | 10.21 Mn |
| Sep 30, 2024 | 9.04 Mn |
| Jun 30, 2024 | 9.91 Mn |
| Mar 31, 2024 | 10.31 Mn |
| Dec 31, 2023 | 11.54 Mn |
| Sep 30, 2023 | 10.06 Mn |
| Jun 30, 2023 | 12.26 Mn |
| Mar 31, 2023 | 12.66 Mn |
| Dec 31, 2022 | 10.96 Mn |
| Sep 30, 2022 | 13.19 Mn |
| Jun 30, 2022 | 13.74 Mn |
| Mar 31, 2022 | 12.52 Mn |
| Dec 31, 2021 | 12.71 Mn |
| Sep 30, 2021 | 11.17 Mn |